Paclitaxel activity, dose, and schedule: Data from phase III trials in metastatic breast cancer

Seminars in Oncology

Volumn 26, Issue 3 SUPPL. 8, 1999, Pages 27-32

  Di Leo, A ^a   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; HUMAN; METASTASIS; METASTASIS INHIBITION; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032970343     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)